A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Completed · Phase 3 · NCT05628103

Conditions: Schizophrenia

Research payments reported, 2025: $88,165
U.S. investigators named: 8
Sites paid: 8
Planned or actual enrollment: 101

About the trial

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Tested: SEP-363856 (drug)
Dates: Started 2022-12-19; completion 2024-04-01
Results posted: Yes

This study evaluated how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.

From ClinicalTrials.gov, last updated 2025-12-11. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sumitomo Pharma America, Inc. reported $88,165 in research payments for this study in 2025 (27 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it